Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial
Condition: Stage III Non-small Cell Lung Cancer Interventions: Drug: Toripalimab; Drug: JS004; Drug: Pemetrexed; Drug: Nab-paclitaxel; Drug: Carboplatin; Procedure: Surgery Sponsor: Shanghai Pulmonary Hospital, Shanghai, China Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Alimta | Cancer | Cancer & Oncology | Chemotherapy | China Health | Hospitals | Lung Cancer | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Non-Small Cell Lung Cancer | Research